Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00521
|
|||||
| Drug Name |
Clonidine
|
|||||
| Synonyms |
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; Adesipress; CATAPRES-TTS-1; CATAPRES-TTS-2; CATAPRES-TTS-3; Catapres (TN); Catapres-TTS; Catapresan; Catapressan; Catarpres; Catarpres-TTS; Catarpres-TTS (TN); Catarpresan; Chlornidinum; Clofenil; Clonidin; Clonidina; Clonidina [INN-Spanish]; Clonidine (JAN/USAN/INN); Clonidine [USAN:BAN:INN]; Clonidinhydrochlorid; Clonidinum; Clonidinum [INN-Latin]; Clopheline; Dixarit; Duraclon; Duraclont; Gemiton; Hemiton; Isoglaucon; Klofelin; Klofenil; M 5041T; M-5041T; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; SKF 34427; ST 155BS; ST-155-BS; ST-155BS; Tenso-Timelets
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11:BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H9Cl2N3
|
|||||
| Canonical SMILES |
C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
|
|||||
| InChI |
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
|
|||||
| InChIKey |
GJSURZIOUXUGAL-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 4205-90-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 230.09 | Topological Polar Surface Area | 36.4 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
1.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10522369
,10527768
,11110984
,11110985
,11113648
,11120350
,11120838
,11121326
,11121653
,11122133
,11335949
,11361188
,11362722
,11364235
,11365284
,11366797
,11367846
,11369359
,11370715
,11370716
,11371375
,11373447
,11374710
,11376008
,11377521
,11462160
,11466276
,11467396
,11484969
,11485991
,11489003
,11490174
,11492771
,11495155
,14822899
,15172366
,26697416
,26697467
,26751841
,26751842
,29221958
,46508119
,47216577
,4807400
,5991864
,7847347
,7978974
,8151812
,840960
,841959
|
|||||
| ChEBI ID |
ChEBI:46632
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| 2-Oct | Transporter Info | Organic cation transporter 2 | Substrate | [2] | ||
| 3-Oct | Transporter Info | Organic cation transporter 3 | Substrate | [2] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Clonidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145. | |||||
| 3 | Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.